Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 9/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420477 | 1.00 | JAK3 (0.41) | JAK3GSK3BPIK3C3NPC1RAB9A | |
| SCHEMBL26888293 | 0.90 | PIK3C3 (0.45) | JAK3GSK3BPIK3C3MAPK1MAPK14 | |
| SCHEMBL30633351 | 0.90 | PIK3C3 (0.45) | JAK3GSK3BPIK3C3MAPK1MAPK14 | |
| SCHEMBL31420740 | 0.90 | PIK3C3 (0.45) | JAK3GSK3BPIK3C3MAPK1MAPK14 | |
| SCHEMBL26686349 | 0.85 | PIK3C3 (0.41) | GSK3BPIK3C3MAPK14 | |
| SCHEMBL31420562 | 0.85 | PIK3C3 (0.41) | GSK3BPIK3C3MAPK14 | |
| SCHEMBL26686694 | 0.85 | PIK3C3 (0.42) | GSK3BPIK3C3MAPK1 | |
| SCHEMBL30633291 | 0.84 | PIK3C3 (0.51) | PIK3C3 | |
| SCHEMBL31420510 | 0.84 | PIK3C3 (0.51) | PIK3C3 | |
| SCHEMBL26888164 | 0.84 | PIK3C3 (0.51) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |